References
- Luft FC. STOPPING at the CAPPP of good HOPE. Nephrol Dial Transplant 2000; 15: 451–2.
- Chalmers J. WHO-ISH Hypertension Guidelines Commit-tee. 1999 Guidelines for Management of Hypertension. J Hypertens 1999; 17: 151–83.
- Joint National Committee. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 1997; 157: 2413–46.
- Neutel J, Weber M, Pool J, et al. Valsartan, a new angiotensin II antagonist: antihypertensive effects over 24 hours. Clin Ther 1997; 19: 447–58.
- Colhoun HM, Dong W, Poulter NR. Blood pressure screening, management and control in England: results from the health survey for England 1994. J Hypertens 1998; 16: 747–52.
- Chamontin B, Poggi L, Lang T, et al. Prevalence, treatment, and control of hypertension in the French population: data from a survey on high blood pressure in general practice, 1994. Am J Hypertens 1998; 11(6 Pt 1): 759–62.
- Marques-Vidal P, Tuomilehto J. Hypertension awareness, treatment and control in the community: is the 'rule of halves' still valid? J Hum Hypertens 1997; 11: 213–20.
- Materson BJ, Reda DJ, Cushman WC. Department of veterans Affairs single-drug therapy of hypertension study. Revised figures and new data. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Am J Hypertens 1995; 8: 189–92.
- Pool J, Oparil S, Hedner T, Glazer R, Oddou-Stock P, Hester A. Dose-responsive antihypertensive efficacy of valsartan, a new angiotensin II-receptor blocker. Clin Ther 1998; 20: 1106–14.
- Bodin F. Pharmacological and clinical profile of valsartan. J Hypertens 2000; 18 Suppl 2: S1–7.
- Parving H-H, Lehnert H, Brochner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870–8.
- Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861–9.
- Maggioni A, Anand I, Gottlieb S, Latini R, Tognoni G, Cohn J. Effects of valsartan on morbidity and mortality in patients with heart failure not receiving ACE-inhibitors. J Am Coll Cardiol 2002; 40: 1414–21.
- Burt VL, Culter JA, Higgins M, et al. Trends in the prevalence, awareness, treatment, and control of hyperten-sion in the adult US population. Data from the health examination surveys, 1960 to 1991. Hypertension 1995; 26: 60–9.
- Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hyper-tension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998; 351: 1755–62.
- SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA 1991; 265: 3255–64.
- Dahl& B, Lindholm LH, Hansson L, Schersten B, Ekbom T, Wester PO. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet 1991; 338: 1281–5.
- Benz JR, Black HR, Graff A, Reed A, Fitzsimmons S, Shi Y. Valsartan and hydrochlorothiazide in patients with essential hypertension. A multiple dose, double-blind, placebo controlled trial comparing combination therapy with mono-therapy. J Hum Hypertens 1998; 12: 861–6.
- Schrier RW. Treating hypertension in the elderly. Am J Geriatr Cardiol 2001; 10: 355–65.
- MacMahon S, Rodgers A. The effects of blood pressure reduction in older patients: an overview of five randomized controlled trials in elderly hypertensives. Clin Exp Hyper-tens 1993; 15: 967–78.
- Hansson L. 'Why don't you do as I tell you?' Compliance and anti-hypertensive regimes. Int J Clin Pract 2002; 56: 191–6.
- Markham A, Goa KL. Valsartan. A review of its pharmacology and therapeutic use in essential hypertension. Drugs 1997; 54: 299–311.
- Neutel JM, Bedigian MP. Efficacy of valsartan in patients aged > or =65 years with systolic hypertension. Clin Ther 2000; 22: 961–9.
- Bremner AD, Baur M, Oddou-Stock P, Bodin F. Valsartan: long-term efficacy and tolerability compared to lisinopril in elderly patients with essential hypertension. Clin Exp Hypertens 1997; 19: 1263–85.